No Data
No Data
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
– Presentation highlights beneficial effects of chronic EDG-7500 treatment in preventing diastolic dysfunction in an animal model of non-obstructive hypertrophic cardiomyopathy (HCM) –BOULDER, Colo.--
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Cantor Virtual Mus
Express News | RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $28 Price Target
RBC Capital Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX)
Edgewise Therapeutics Initiated at Overweight by Piper Sandler
Edgewise Therapeutics Initiated at Overweight by Piper Sandler
Piper Sandler Initiates Coverage On Edgewise Therapeutics With Overweight Rating, Announces Price Target of $48
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Edgewise Therapeutics with a Overweight rating and announces Price Target of $48.
No Data